

# Smallpox - Pipeline Review, H1 2020

https://marketpublishers.com/r/SF36B247ACBEN.html Date: January 2020 Pages: 81 Price: US\$ 2,000.00 (Single User License) ID: SF36B247ACBEN

### **Abstracts**

Smallpox - Pipeline Review, H1 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Smallpox - Pipeline Review, H1 2020, provides an overview of the Smallpox (Infectious Disease) pipeline landscape.

Smallpox is an acute contagious infection caused by the Variola virus. Symptoms include fever, malaise, headache, prostration, severe back pain, abdominal pain and vomiting. This is followed by the development of rashes on the face, hands, forearms and the trunk. Lesions develop in the mucous membranes of the nose and mouth which ulcerate, releasing large amounts of virus into the mouth and throat. Treatment includes medications such as antiviral and lifestyle modification.

### **REPORT HIGHLIGHTS**

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Smallpox -Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Smallpox (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Smallpox (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Smallpox and features dormant and discontinued projects. The guide covers therapeutics under Development by



Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 2, 1, 4 and 3 respectively.

Smallpox (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

### SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Smallpox (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Smallpox (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Smallpox (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Smallpox (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline



projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Smallpox (Infectious Disease)

#### **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Smallpox (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Smallpox (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



### Contents

| Introduction<br>Global Markets Direct Report Coverage<br>Smallpox - Overview<br>Smallpox - Therapeutics Development<br>Pipeline Overview<br>Pipeline by Companies<br>Products under Development by Companies |
|--|
| Smallpox - Therapeutics Assessment   |
| Assessment by Target   |
| Assessment by Mechanism of Action  |
| Assessment by Route of Administration  |
| Assessment by Molecule Type  |
| Smallpox - Companies Involved in Therapeutics Development  |
| Bavarian Nordic A/S  |
| BioFactura Inc   |
| CEL-SCI Corp   |
| Chimerix Inc   |
| CJ HealthCare Corp   |
| EpiVax Inc   |
| Polyrizon Ltd  |
| SIGA Technologies Inc  |
| Tonix Pharmaceuticals Holding Corp<br>Viraze   |
| Smallpox - Drug Profiles   |
| brincidofovir - Drug Profile   |
| Product Description  |
| Mechanism Of Action  |
| R&D Progress   |
| CEL-1000 - Drug Profile  |
| Product Description  |
| Mechanism Of Action  |
| R&D Progress   |
| CJ-40011 - Drug Profile  |
| Product Description  |
| Mechanism Of Action  |
| R&D Progress   |
| Monoclonal Antibody for Smallpox - Drug Profile  |
|  |



**Product Description** 

- Mechanism Of Action
- R&D Progress
- PL-801 Drug Profile
- Product Description
- Mechanism Of Action
- **R&D** Progress
- smallpox and monkeypox [ankara] vaccine Drug Profile
- **Product Description**
- Mechanism Of Action
- R&D Progress
- smallpox vaccine Drug Profile
- **Product Description**
- Mechanism Of Action
- **R&D** Progress
- tecovirimat Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- TNX-801 Drug Profile
- **Product Description**
- Mechanism Of Action
- R&D Progress
- VIR-002 Drug Profile
- Product Description
- Mechanism Of Action
- **R&D** Progress
- Smallpox Dormant Projects
- Smallpox Discontinued Products
- Smallpox Product Development Milestones
- Featured News & Press Releases
- Appendix



### **List Of Tables**

#### LIST OF TABLES

Number of Products under Development for Smallpox, H1 2020 Number of Products under Development by Companies, H1 2020 Products under Development by Companies, H1 2020 Number of Products by Stage and Target, H1 2020 Number of Products by Stage and Mechanism of Action, H1 2020 Number of Products by Stage and Route of Administration, H1 2020 Number of Products by Stage and Molecule Type, H1 2020 Smallpox - Pipeline by Bavarian Nordic A/S, H1 2020 Smallpox - Pipeline by BioFactura Inc, H1 2020 Smallpox - Pipeline by CEL-SCI Corp, H1 2020 Smallpox - Pipeline by Chimerix Inc, H1 2020 Smallpox - Pipeline by CJ HealthCare Corp, H1 2020 Smallpox - Pipeline by EpiVax Inc, H1 2020 Smallpox - Pipeline by Polyrizon Ltd, H1 2020 Smallpox - Pipeline by SIGA Technologies Inc, H1 2020 Smallpox - Pipeline by Tonix Pharmaceuticals Holding Corp, H1 2020 Smallpox - Pipeline by Viraze, H1 2020 Smallpox - Dormant Projects, H1 2020 Smallpox - Dormant Projects, H1 2020 (Contd..1), H1 2020

Smallpox - Discontinued Products, H1 2020



## **List Of Figures**

#### LIST OF FIGURES

Number of Products under Development for Smallpox, H1 2020 Number of Products under Development by Companies, H1 2020 Number of Products by Targets, H1 2020 Number of Products by Stage and Targets, H1 2020 Number of Products by Mechanism of Actions, H1 2020 Number of Products by Stage and Mechanism of Actions, H1 2020 Number of Products by Routes of Administration, H1 2020 Number of Products by Stage and Routes of Administration, H1 2020 Number of Products by Stage and Routes of Administration, H1 2020 Number of Products by Molecule Types, H1 2020 Number of Products by Stage and Molecule Types, H1 2020

### **COMPANIES MENTIONED**

Bavarian Nordic A/S BioFactura Inc CEL-SCI Corp Chimerix Inc CJ HealthCare Corp EpiVax Inc Polyrizon Ltd SIGA Technologies Inc Tonix Pharmaceuticals Holding Corp Viraze



### I would like to order

Product name: Smallpox - Pipeline Review, H1 2020

Product link: https://marketpublishers.com/r/SF36B247ACBEN.html

Price: US\$ 2,000.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: <u>info@marketpublishers.com</u>

### Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/SF36B247ACBEN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

\*\*All fields are required

Custumer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970